NO20062509L - Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav - Google Patents

Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav

Info

Publication number: NO20062509L
Authority: NO; Norway
Prior art keywords: inhibitors; present; treatment; methods; compound
Prior art date: 2003-10-31

Application number

NO20062509A

Other languages

English (en)

Norwegian (no)

Inventor

Graeme Semple

Thomas Schrader

Phillip J Skinner

Steven L Colletti

Tawfik Gharbaoui

Jason Imbriglio

Jae-Kyu Jung

Rui Liang

Subharekha Raghavan

Darby Schmidt

James R Tata

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-31

Filing date

2006-05-31

Publication date

2006-06-26

2006-05-31 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2006-06-26 Publication of NO20062509L publication Critical patent/NO20062509L/no

Links

238000000034 method Methods 0.000 title abstract 2
150000003536 tetrazoles Chemical class 0.000 title abstract 2
208000030159 metabolic disease Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
239000003112 inhibitor Substances 0.000 abstract 2
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 abstract 1
229940077274 Alpha glucosidase inhibitor Drugs 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
229940123208 Biguanide Drugs 0.000 abstract 1
208000032928 Dyslipidaemia Diseases 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
239000003288 aldose reductase inhibitor Substances 0.000 abstract 1
229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 abstract 1
239000003888 alpha glucosidase inhibitor Substances 0.000 abstract 1
150000004283 biguanides Chemical class 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
208000029078 coronary artery disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract 1
239000003623 enhancer Substances 0.000 abstract 1
229940125753 fibrate Drugs 0.000 abstract 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000000144 pharmacologic effect Effects 0.000 abstract 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229940031439 squalene Drugs 0.000 abstract 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20062509A 2003-10-31 2006-05-31 Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav NO20062509L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51623803P	2003-10-31	2003-10-31
PCT/US2004/035927 WO2005044816A1 (fr)	2003-10-31	2004-10-29	Derives de tetrazole et methodes de traitement de troubles lies au metabolisme

Publications (1)

Publication Number	Publication Date
NO20062509L true NO20062509L (no)	2006-06-26

Family

ID=34572875

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20062509A NO20062509L (no)	2003-10-31	2006-05-31	Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav

Country Status (37)

Country	Link
US (2)	US8637555B2 (fr)
EP (2)	EP1683794A1 (fr)
JP (2)	JP4533898B2 (fr)
KR (1)	KR100850591B1 (fr)
CN (1)	CN1867562B (fr)
AR (1)	AR046611A1 (fr)
AT (1)	ATE328880T1 (fr)
AU (1)	AU2004287861B2 (fr)
BR (1)	BRPI0415631A (fr)
CA (1)	CA2539985C (fr)
CO (1)	CO5690551A2 (fr)
CR (1)	CR8270A (fr)
CY (1)	CY1105479T1 (fr)
DE (1)	DE602004001134T2 (fr)
DK (1)	DK1599469T3 (fr)
EA (1)	EA011484B1 (fr)
EC (1)	ECSP066529A (fr)
ES (1)	ES2267077T3 (fr)
GE (1)	GEP20094801B (fr)
HR (1)	HRP20060286T3 (fr)
IL (1)	IL174042A0 (fr)
IS (1)	IS2372B (fr)
MA (1)	MA28171A1 (fr)
MX (1)	MXPA06004556A (fr)
MY (1)	MY140410A (fr)
NO (1)	NO20062509L (fr)
NZ (1)	NZ546285A (fr)
PE (1)	PE20050483A1 (fr)
PL (1)	PL1599469T3 (fr)
PT (1)	PT1599469E (fr)
RS (1)	RS20060290A (fr)
SI (1)	SI1599469T1 (fr)
TN (1)	TNSN06150A1 (fr)
TW (1)	TWI258478B (fr)
UA (1)	UA86783C2 (fr)
WO (1)	WO2005044816A1 (fr)
ZA (2)	ZA200603419B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1603585A2 (fr)	2003-03-14	2005-12-14	Bristol-Myers Squibb Company	Polynucleotide codant un nouveau variant de recepteur de hm74, hgprbmy74 couple a une proteine g humaine
PE20050483A1 (es)	2003-10-31	2005-08-25	Arena Pharm Inc	Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
JP2007512346A (ja) *	2003-11-21	2007-05-17	アリーナファーマシューティカルズ，インコーポレイテッド	４−オキソ−４，５−ジヒドロ−フラン−２−カルボン酸誘導体およびその代謝関連障害の処置方法
US20070244107A1 (en) *	2004-08-25	2007-10-18	Waters M Gerard	Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
AU2005305086A1 (en) *	2004-11-05	2006-05-18	Arena Pharmaceuticals, Inc.	Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
PE20060949A1 (es)	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006114581A1 (fr) *	2005-04-28	2006-11-02	Merck Sharp & Dohme Limited	Procede de fabrication de tetrazolyltetrahydrocyclopentapyrazoles
CA2611552A1 (fr)	2005-06-28	2007-01-04	Merck & Co., Inc.	Agonistes du recepteur de la niacine, compositions contenant de tels composes et procedes de traitement
DE102006021733A1 (de) *	2006-05-09	2007-11-22	Bayer Healthcare Ag	3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006043443A1 (de)	2006-09-15	2008-03-27	Bayer Healthcare Ag	Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102008063992A1 (de)	2008-12-19	2010-09-02	Lerner, Zinoviy, Dipl.-Ing.	Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102010021637A1 (de)	2010-05-26	2011-12-01	Bayer Schering Pharma Aktiengesellschaft	Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CA2878625A1 (fr)	2012-07-11	2014-01-16	Elcelyx Therapeutics, Inc.	Compositions comportant des statines, des biguanides et d'autres agents pour reduire un risque cardiometabolique
EP3760629A1 (fr)	2013-02-21	2021-01-06	Adverio Pharma GmbH	Formes du {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}méthylcarbamate de méthyle
JP6453216B2 (ja) *	2013-07-23	2019-01-16	エーザイ・アール・アンド・ディー・マネジメント株式会社	ヘテロ縮合環化合物
CN103755637A (zh) *	2013-12-26	2014-04-30	平湖优康药物研发有限公司	一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺
US12086719B2 (en) *	2019-10-11	2024-09-10	Royal Bank Of Canada	System and method of machine learning using embedding networks

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH02178263A (ja) *	1988-12-27	1990-07-11	Kaken Pharmaceut Co Ltd	アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤
US5134155A (en)	1991-08-08	1992-07-28	Ortho Pharmaceutical Corporation	Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
US5948786A (en)	1996-04-12	1999-09-07	Sumitomo Pharmaceuticals Company, Limited	Piperidinylpyrimidine derivatives
AU730224B2 (en)	1996-12-23	2001-03-01	Du Pont Pharmaceuticals Company	Nitrogen containing heteroaromatics as factor Xa inhibitors
US6506757B1 (en)	1998-03-10	2003-01-14	Ono Pharmaceutical Co., Ltd.	Carboxylic acid derivatives and drugs containing the same as the active ingredient
US6414002B1 (en)	1999-09-22	2002-07-02	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
MXPA02008801A (es)	2000-03-09	2003-07-07	Ono Pharmaceutical Co	Derivados de indol, proceso para la preparacion de los mismos y su uso.
US20010047027A1 (en)	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
US6699997B2 (en)	2000-06-28	2004-03-02	Teva Pharmaceutical Industries Ltd.	Carvedilol
IL153111A0 (en)	2000-06-30	2003-06-24	Glaxo Group Ltd	Quinazoline ditosylate salt compounds
US6410583B1 (en)	2000-07-25	2002-06-25	Merck Frosst Canada & Co.	Cyclopentanoindoles, compositions containing such compounds and methods of treatment
DE10057751A1 (de)	2000-11-22	2002-05-23	Bayer Ag	Neue Carbamat-substituierte Pyrazolopyridinderivate
ES2272712T3 (es)	2001-05-23	2007-05-01	Merck Frosst Canada Ltd.	Derivados de dihidropirrolo-1,2-aiindol y tetrahidropirido -1,2-aiindol como antagonistas de receptores de prostaglandina d2.
DK1397351T3 (da)	2001-06-01	2010-01-18	Hoffmann La Roche	Pyrimidin-, triazin- og pyrazinderivater som glutamatreceptorer
HUP0401711A3 (en)	2001-06-26	2009-07-28	Bristol Myers Squibb Co	N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them
JP3968076B2 (ja)	2001-06-27	2007-08-29	アールエステックコーポレイション	新しいキラルサレン化合物、キラルサレン触媒及びこれを利用したラセミックエポキシ化合物からキラル化合物を製造する方法
CA2459515A1 (fr)	2001-09-07	2003-03-20	Kazuhiko Torisu	Derives d'indole
DE10148617A1 (de)	2001-09-25	2003-04-24	Schering Ag	Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AR038136A1 (es)	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
MXPA04009095A (es)	2002-03-19	2004-12-06	Ono Pharmaceutical Co	Compuesto de acido carboxilico y agente farmaceutico que comprende el compuesto como ingrediente activo.
DE10220570A1 (de)	2002-05-08	2003-11-20	Bayer Ag	Carbamat-substituierte Pyrazolopyridine
AU2003282679A1 (en)	2002-10-04	2004-05-04	Arena Pharmaceuticals, Inc.	Hydroxypyrazoles for use against metabolic-related disorders
EP1551403B1 (fr) *	2002-10-10	2009-04-29	Arena Pharmaceuticals, Inc.	Derives d'acide 2h-pyrazole-3-carboxylique substitue en 5 utilises en tant qu'agents antilipotyques pour le traitement de troubles metaboliques, tels que la dyslipidemie
DE10261131A1 (de)	2002-12-20	2004-07-01	Grünenthal GmbH	Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
US7145012B2 (en)	2003-04-23	2006-12-05	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
AR041089A1 (es)	2003-05-15	2005-05-04	Merck & Co Inc	Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
US7232823B2 (en)	2003-06-09	2007-06-19	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
AU2004260636A1 (en)	2003-06-13	2005-02-10	Arena Pharmaceuticals, Inc.	5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor RUP25 for the treatment of dyslipidemia and related diseases
GB0319126D0 (en)	2003-08-14	2003-09-17	Smithkline Beecham Corp	Chemical compounds
GB0319124D0 (en)	2003-08-14	2003-09-17	Smithkline Beecham Corp	Chemical compounds
PE20050483A1 (es)	2003-10-31	2005-08-25	Arena Pharm Inc	Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
CA2556073C (fr)	2004-02-14	2012-01-10	Smithkline Beecham Corporation	Composes
US20070244107A1 (en)	2004-08-25	2007-10-18	Waters M Gerard	Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
AU2005305086A1 (en)	2004-11-05	2006-05-18	Arena Pharmaceuticals, Inc.	Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
PE20060949A1 (es)	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006114581A1 (fr)	2005-04-28	2006-11-02	Merck Sharp & Dohme Limited	Procede de fabrication de tetrazolyltetrahydrocyclopentapyrazoles

2004
- 2004-10-27 PE PE2004001031A patent/PE20050483A1/es not_active Application Discontinuation
- 2004-10-27 TW TW093132486A patent/TWI258478B/zh not_active IP Right Cessation
- 2004-10-28 MY MYPI20044462A patent/MY140410A/en unknown
- 2004-10-29 UA UAA200605989A patent/UA86783C2/ru unknown
- 2004-10-29 GE GEAP20049421A patent/GEP20094801B/en unknown
- 2004-10-29 HR HR20060286T patent/HRP20060286T3/xx unknown
- 2004-10-29 AR ARP040103978A patent/AR046611A1/es unknown
- 2004-10-29 JP JP2006536942A patent/JP4533898B2/ja not_active Expired - Fee Related
- 2004-10-29 US US10/535,345 patent/US8637555B2/en not_active Expired - Fee Related
- 2004-10-29 PL PL04818324T patent/PL1599469T3/pl unknown
- 2004-10-29 DK DK04818324T patent/DK1599469T3/da active
- 2004-10-29 AT AT04818324T patent/ATE328880T1/de active
- 2004-10-29 CN CN2004800299376A patent/CN1867562B/zh not_active Expired - Fee Related
- 2004-10-29 EP EP06005248A patent/EP1683794A1/fr not_active Withdrawn
- 2004-10-29 AU AU2004287861A patent/AU2004287861B2/en not_active Ceased
- 2004-10-29 PT PT04818324T patent/PT1599469E/pt unknown
- 2004-10-29 BR BRPI0415631-5A patent/BRPI0415631A/pt not_active IP Right Cessation
- 2004-10-29 WO PCT/US2004/035927 patent/WO2005044816A1/fr not_active Ceased
- 2004-10-29 EP EP04818324A patent/EP1599469B1/fr not_active Expired - Lifetime
- 2004-10-29 RS YUP-2006/0290A patent/RS20060290A/sr unknown
- 2004-10-29 ES ES04818324T patent/ES2267077T3/es not_active Expired - Lifetime
- 2004-10-29 KR KR1020067008311A patent/KR100850591B1/ko not_active Expired - Fee Related
- 2004-10-29 SI SI200430058T patent/SI1599469T1/sl unknown
- 2004-10-29 MX MXPA06004556A patent/MXPA06004556A/es active IP Right Grant
- 2004-10-29 NZ NZ546285A patent/NZ546285A/en not_active IP Right Cessation
- 2004-10-29 EA EA200600879A patent/EA011484B1/ru not_active IP Right Cessation
- 2004-10-29 CA CA2539985A patent/CA2539985C/fr not_active Expired - Fee Related
- 2004-10-29 DE DE602004001134T patent/DE602004001134T2/de not_active Expired - Lifetime
2006
- 2006-03-01 IL IL174042A patent/IL174042A0/en unknown
- 2006-03-03 CR CR8270A patent/CR8270A/es not_active Application Discontinuation
- 2006-03-30 CO CO06031620A patent/CO5690551A2/es not_active Application Discontinuation
- 2006-04-28 ZA ZA200603419A patent/ZA200603419B/en unknown
- 2006-04-28 EC EC2006006529A patent/ECSP066529A/es unknown
- 2006-05-22 TN TNP2006000150A patent/TNSN06150A1/en unknown
- 2006-05-23 MA MA29049A patent/MA28171A1/fr unknown
- 2006-05-24 IS IS8481A patent/IS2372B/is unknown
- 2006-05-31 NO NO20062509A patent/NO20062509L/no not_active Application Discontinuation
- 2006-07-26 ZA ZA200606203A patent/ZA200606203B/xx unknown
- 2006-09-05 CY CY20061101259T patent/CY1105479T1/el unknown
- 2006-11-17 US US11/601,252 patent/US20070072924A1/en not_active Abandoned
2010
- 2010-03-10 JP JP2010053852A patent/JP2010163448A/ja active Pending

Also Published As

Publication number	Publication date
US20060217562A1 (en)	2006-09-28
EP1599469B1 (fr)	2006-06-07
HK1076468A1 (en)	2006-01-20
IL174042A0 (en)	2006-08-01
DK1599469T3 (da)	2006-10-09
KR20060073974A (ko)	2006-06-29
AU2004287861A1 (en)	2005-05-19
IS8481A (is)	2006-05-24
MY140410A (en)	2009-12-31
US8637555B2 (en)	2014-01-28
PL1599469T3 (pl)	2006-10-31
JP4533898B2 (ja)	2010-09-01
TNSN06150A1 (en)	2007-11-15
AR046611A1 (es)	2005-12-14
HRP20060286T3 (en)	2007-03-31
KR100850591B1 (ko)	2008-08-05
WO2005044816A1 (fr)	2005-05-19
DE602004001134D1 (de)	2006-07-20
MA28171A1 (fr)	2006-09-01
RS20060290A (sr)	2008-11-28
PE20050483A1 (es)	2005-08-25
CN1867562A (zh)	2006-11-22
EA200600879A1 (ru)	2006-10-27
AU2004287861B2 (en)	2008-08-14
TW200530221A (en)	2005-09-16
BRPI0415631A (pt)	2006-12-12
JP2010163448A (ja)	2010-07-29
CN1867562B (zh)	2011-07-13
EP1683794A1 (fr)	2006-07-26
CY1105479T1 (el)	2010-07-28
JP2007509181A (ja)	2007-04-12
NZ546285A (en)	2010-04-30
SI1599469T1 (sl)	2006-10-31
EA011484B1 (ru)	2009-04-28
CR8270A (es)	2006-10-06
MXPA06004556A (es)	2006-07-06
ECSP066529A (es)	2006-10-10
IS2372B (is)	2008-06-15
EP1599469A1 (fr)	2005-11-30
ES2267077T3 (es)	2007-03-01
CA2539985C (fr)	2010-02-16
CA2539985A1 (fr)	2005-05-19
CO5690551A2 (es)	2006-10-31
ATE328880T1 (de)	2006-06-15
GEP20094801B (en)	2009-10-26
DE602004001134T2 (de)	2007-04-19
UA86783C2 (ru)	2009-05-25
ZA200606203B (en)	2007-04-25
US20070072924A1 (en)	2007-03-29
PT1599469E (pt)	2006-10-31
ZA200603419B (en)	2006-10-25
TWI258478B (en)	2006-07-21

Legal Events

Date	Code	Title	Description
2013-05-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20073766L (no)	2007-09-21	Smeltede pyrazolderivater og fremgangsmater for behandling av metabolsk-relaterte lidelser derav
WO2004033431A3 (fr)	2004-07-29	Hydroxypyrazoles et methodes prophylactiques ou de traitement de troubles lies au metabolisme
NO20062509L (no)	2006-06-26	Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav
EP3129023B1 (fr)	2021-02-24	Puissants inhibiteurs d'époxyde hydrolase soluble
US9447134B2 (en)	2016-09-20	Compounds and methods for treating mammalian gastrointestinal microbial infections
PH12014500937A1 (en)	2015-09-21	5-ht 1a receptor substype agonist
NZ587547A (en)	2012-09-28	Modulators of ATP-Binding Cassette Transporters
CA2537127A1 (fr)	2005-03-10	Composes de benzimidazolone a activite d'agonistes du recepteur 5-ht4
MX2009006474A (es)	2009-06-26	Derivados de benzamida como agonistas del receptor ep4.
MX2007010532A (es)	2007-10-12	Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
WO2010136474A3 (fr)	2011-01-20	Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
CA2554550A1 (fr)	2005-08-11	Antagonistes des recepteurs de l'hydroisoindoline tachykinine
CA2545092A1 (fr)	2005-06-02	Composes d'acide quinolonecarboxylique a activite agoniste du recepteur 5-ht4
NO20051901L (no)	2005-04-19	Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger
CA2615611A1 (fr)	2007-01-25	Derives d'indazolecarboxamides en tant qu'agonistes des recepteurs 5ht4
JP5765738B2 (ja)	2015-08-19	ロスバスタチンおよびアトルバスタチン誘導体
DE60327446D1 (de)	2009-06-10	5-substituierte 2h-pyrazon-3-carbonsäure-derivate als antilipolytische mittel zur behandlung von stoffwechselstörungen, wie z.b. dyslipidemie
WO2005051937A3 (fr)	2005-09-15	Derives d'acide carboxylique 4-oxo-4,5-dihydrofurane-2 et methodes pour traiter des troubles du metabolisme
WO2003018010A1 (fr)	2003-03-06	Agent prophylactique et/ou curatif pour les maladies induites par l'activite de l'arteriosclerose
Kato et al.	2013	Discovery of 2, 8-diazaspiro [4.5] decane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating hypertension
NO932382L (no)	1993-06-29	Heterocykliske forbindelser
UA90878C2 (ru)	2010-06-10	Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ
WO2008146917A1 (fr)	2008-12-04	Dérivés de la lincomycine et agents antibactériens les contenant en tant qu'ingrédient actif
WO2003018564A1 (fr)	2003-03-06	Inhibiteur d'acat selectif de la paroi vasculaire
TW200722522A (en)	2007-06-16	New compound colletoic acid